Loading stock data…
OMCL
$42.80+1.38 (+3.33%)
Market ClosedLast close May 1
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Omnicell, Inc. in the Healthcare sector is trading at $42.80. The stock is currently 22% below its 52-week high of $55.00, remaining 16.2% above its 200-day moving average. Technical signals show neutral RSI of 70 and bullish MACD crossover, explaining why OMCL maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 70) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$42.80
Potential Downside
98%
Whystock Fair Value$0.86
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the heal...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.67B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
916.25
Beta
Defensive asset. Lower volatility than the S&P 500.
0.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
1.87%
Volume
Today's trading volume
616,909
Recent News
Omnicell Q1 Earnings & Revenues Top, Stock Up, Gross Margin Rises
OMCL posts Q1 earnings and revenue beat with surging margins and strong demand, sending shares sharply higher after results.
Investment Advisor Sells $6.6 Million Worth of Medical Solutions Stock, According to Recent SEC Filing
Omnicell provides automation and software solutions to streamline medication management for healthcare systems and pharmacies.
Omnicell Inc (OMCL) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Positive ...
Omnicell Inc (OMCL) reports a 15% year-over-year revenue increase and unveils promising new products, despite facing challenges in the retail pharmacy segment.
Why Omnicell Stock Trounced the Market on Tuesday
The healthcare tech company posted strong quarterly results.
Omnicell (OMCL) Q1 2025 Earnings Transcript
This call will contain certain forward-looking statements, including statements related to financial projections or performance or other statements regarding Omnicell's plans, strategy, objectives, goals, vision, expectations, planned investments, opportunities, expense mitigation, products, services or solution, driving toward a recurring revenue model, navigating the current macroeconomic environment, the impact of or ability to mitigate the impact of, tariffs, or market or company outlook that are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. For a more detailed description of the risks that impact these forward-looking statements, please refer to the information in our press release issued today, in the Omnicell Annual Report on Form 10-K filed with the SEC on February 27, 2025, and in other more recent reports filed with the SEC.